Cyamemazine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cyamemazine" in English language version.

refsWebsite

Global rank English rank

11doi.org

2^nd place

11nih.gov

4^th place

4semanticscholar.org

11^th place

8^th place

3books.google.com

3^rd place

1archive.today

14^th place

1masson.fr

low place

1cambridge.org

305^th place

264^th place

1web.archive.org

1^st place

1springer.de

low place

1espacenet.com

800^th place

676^th place

archive.today

Bret P, Bret MC, Queuille E (April 2009). "[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]". L'Encephale (in French). 35 (2): 129–138. doi:10.1016/j.encep.2008.03.007. PMID 19393381. Archived from the original on 2013-02-13.

books.google.com

Index Nominum, International Drug. Taylor & Francis. 2000. ISBN 978-3-88763-075-1.
Triggle DJ (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. p. 534. ISBN 0-412-46630-9.
Sittig M (January 1988). Pharmaceutical manufacturing ... - Google Books. Noyes Publications. ISBN 9780815511441.

cambridge.org

stahlonline.cambridge.org

"Cyamemazine". Stahl's Essential Psychopharmacology. Cambridge University Press.

doi.org

Bret P, Bret MC, Queuille E (April 2009). "[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]". L'Encephale (in French). 35 (2): 129–138. doi:10.1016/j.encep.2008.03.007. PMID 19393381. Archived from the original on 2013-02-13.
Bourin M, Claude Colombel M, Dib M, Hascoët M (September 2001). "Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice". Behavioural Brain Research. 124 (1): 87–95. doi:10.1016/S0166-4328(01)00238-8. PMID 11423169. S2CID 43312295.
Benyamina A, Naassila M, Bourin M (July 2012). "Potential role of cortical 5-HT(2A) receptors in the anxiolytic action of cyamemazine in benzodiazepine withdrawal". Psychiatry Research. 198 (2). Elsevier BV: 307–312. doi:10.1016/j.psychres.2012.01.009. PMID 22421069. S2CID 34830082.
Bourin M, Dailly E, Hascöet M (2006-06-07). "Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome". CNS Drug Reviews. 10 (3). Wiley: 219–229. doi:10.1111/j.1527-3458.2004.tb00023.x. PMC 6741725. PMID 15492772.
Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M (February 2003). "Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes". Biochemical Pharmacology. 65 (3): 435–440. doi:10.1016/S0006-2952(02)01515-0. PMID 12527336.
Alvarez-Guerra M, d'Alché-Birée F, Wolf WA, Vargas F, Dib M, Garay RP (January 2000). "5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity". Psychopharmacology. 147 (4): 412–417. doi:10.1007/s002130050010. PMID 10672635. S2CID 25162849. Archived from the original on 2002-01-12. Retrieved 2010-02-11.
Alvarez-Guerra M, Hameg A, Bayle F, Dib M, Garay RP (November 2002). "5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle". European Journal of Pharmacology. 454 (2–3): 235–239. doi:10.1016/S0014-2999(02)02489-5. PMID 12421652.
Benyamina A, Arbus C, Nuss P, Garay RP, Neliat G, Hameg A (January 2008). "Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes". European Journal of Pharmacology. 578 (2–3): 142–147. doi:10.1016/j.ejphar.2007.09.025. PMID 17936750.
Peinado J, Hameg A, Garay RP, Bayle F, Nuss P, Dib M (February 2003). "Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine". Naunyn-Schmiedeberg's Archives of Pharmacology. 367 (2): 134–139. doi:10.1007/s00210-002-0665-4. PMID 12595954. S2CID 682064.
Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M (February 2003). "Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes". Biochemical Pharmacology. 65 (3): 435–440. doi:10.1016/s0006-2952(02)01515-0. PMID 12527336.
Craig PN, Gordon M, Lafferty JJ, Lester BM, Saggiomo AJ, Zirkle CL (1961). "Synthesis of Phenothiazines. VI. Certain 2-Substituted Phenothiazines and Their 10-Aminoalkyl Derivatives". The Journal of Organic Chemistry. 26 (4): 1138–1143. doi:10.1021/jo01063a040.

espacenet.com

worldwide.espacenet.com

US 2877224, Jacob RM, Georges RJ gdate = 1959, assigned to Rhone Poulenc Sa

masson.fr

Bret P, Bret MC, Queuille E (April 2009). "[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]". L'Encephale (in French). 35 (2): 129–138. doi:10.1016/j.encep.2008.03.007. PMID 19393381. Archived from the original on 2013-02-13.

nih.gov

pubmed.ncbi.nlm.nih.gov

Bret P, Bret MC, Queuille E (April 2009). "[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]". L'Encephale (in French). 35 (2): 129–138. doi:10.1016/j.encep.2008.03.007. PMID 19393381. Archived from the original on 2013-02-13.
Bourin M, Claude Colombel M, Dib M, Hascoët M (September 2001). "Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice". Behavioural Brain Research. 124 (1): 87–95. doi:10.1016/S0166-4328(01)00238-8. PMID 11423169. S2CID 43312295.
Benyamina A, Naassila M, Bourin M (July 2012). "Potential role of cortical 5-HT(2A) receptors in the anxiolytic action of cyamemazine in benzodiazepine withdrawal". Psychiatry Research. 198 (2). Elsevier BV: 307–312. doi:10.1016/j.psychres.2012.01.009. PMID 22421069. S2CID 34830082.
Bourin M, Dailly E, Hascöet M (2006-06-07). "Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome". CNS Drug Reviews. 10 (3). Wiley: 219–229. doi:10.1111/j.1527-3458.2004.tb00023.x. PMC 6741725. PMID 15492772.
Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M (February 2003). "Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes". Biochemical Pharmacology. 65 (3): 435–440. doi:10.1016/S0006-2952(02)01515-0. PMID 12527336.
Alvarez-Guerra M, d'Alché-Birée F, Wolf WA, Vargas F, Dib M, Garay RP (January 2000). "5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity". Psychopharmacology. 147 (4): 412–417. doi:10.1007/s002130050010. PMID 10672635. S2CID 25162849. Archived from the original on 2002-01-12. Retrieved 2010-02-11.
Alvarez-Guerra M, Hameg A, Bayle F, Dib M, Garay RP (November 2002). "5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle". European Journal of Pharmacology. 454 (2–3): 235–239. doi:10.1016/S0014-2999(02)02489-5. PMID 12421652.
Benyamina A, Arbus C, Nuss P, Garay RP, Neliat G, Hameg A (January 2008). "Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes". European Journal of Pharmacology. 578 (2–3): 142–147. doi:10.1016/j.ejphar.2007.09.025. PMID 17936750.
Peinado J, Hameg A, Garay RP, Bayle F, Nuss P, Dib M (February 2003). "Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine". Naunyn-Schmiedeberg's Archives of Pharmacology. 367 (2): 134–139. doi:10.1007/s00210-002-0665-4. PMID 12595954. S2CID 682064.
Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M (February 2003). "Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes". Biochemical Pharmacology. 65 (3): 435–440. doi:10.1016/s0006-2952(02)01515-0. PMID 12527336.

ncbi.nlm.nih.gov

Bourin M, Dailly E, Hascöet M (2006-06-07). "Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome". CNS Drug Reviews. 10 (3). Wiley: 219–229. doi:10.1111/j.1527-3458.2004.tb00023.x. PMC 6741725. PMID 15492772.

semanticscholar.org

api.semanticscholar.org

Bourin M, Claude Colombel M, Dib M, Hascoët M (September 2001). "Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice". Behavioural Brain Research. 124 (1): 87–95. doi:10.1016/S0166-4328(01)00238-8. PMID 11423169. S2CID 43312295.
Benyamina A, Naassila M, Bourin M (July 2012). "Potential role of cortical 5-HT(2A) receptors in the anxiolytic action of cyamemazine in benzodiazepine withdrawal". Psychiatry Research. 198 (2). Elsevier BV: 307–312. doi:10.1016/j.psychres.2012.01.009. PMID 22421069. S2CID 34830082.
Alvarez-Guerra M, d'Alché-Birée F, Wolf WA, Vargas F, Dib M, Garay RP (January 2000). "5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity". Psychopharmacology. 147 (4): 412–417. doi:10.1007/s002130050010. PMID 10672635. S2CID 25162849. Archived from the original on 2002-01-12. Retrieved 2010-02-11.
Peinado J, Hameg A, Garay RP, Bayle F, Nuss P, Dib M (February 2003). "Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine". Naunyn-Schmiedeberg's Archives of Pharmacology. 367 (2): 134–139. doi:10.1007/s00210-002-0665-4. PMID 12595954. S2CID 682064.

springer.de

link.springer.de

Alvarez-Guerra M, d'Alché-Birée F, Wolf WA, Vargas F, Dib M, Garay RP (January 2000). "5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity". Psychopharmacology. 147 (4): 412–417. doi:10.1007/s002130050010. PMID 10672635. S2CID 25162849. Archived from the original on 2002-01-12. Retrieved 2010-02-11.

web.archive.org

Alvarez-Guerra M, d'Alché-Birée F, Wolf WA, Vargas F, Dib M, Garay RP (January 2000). "5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity". Psychopharmacology. 147 (4): 412–417. doi:10.1007/s002130050010. PMID 10672635. S2CID 25162849. Archived from the original on 2002-01-12. Retrieved 2010-02-11.